(Q80316368)

English

Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chroni

scientific article published on 10 May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

multicenter clinical trial

1 reference

based on heuristic

inferred from title

3

object named as

Gratwohl A

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Knop S

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Hebart H

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kliem C

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Faul C

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Holler E

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Apperley J

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kolb HJ

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Schaefer A

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Niederwieser D

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Einsele H

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

10 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1830-1833

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495972%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404731

0 references

How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel strategies for steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose bolus methylprednisolone for the treatment of acute graft versus host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat refractory acute GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies for the prevention and treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404731

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80316368&oldid=1820177153"